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Abstract 
 
Background: Pediatric bipolar (BP) disorder is a prevalent and highly morbid disorder. While structured diagnostic interviews 
have been developed to aid in the diagnosis of pediatric BP disorder, these tools are lengthy, costly and not widely available. 
One possible diagnostic aid is the Child Behavior Checklist (CBCL). 
Objective: To assess the diagnostic utility of the CBCL-BP profile to identify children with a diagnosis of BP-I disorder. 
Method: Subjects were derived from four independent data sets of children and adolescents with and without attention deficit 
hyperactivity disorder and BP-I. Subjects were recruited from pediatric and psychiatric clinics and the community. All subjects 
had structured clinical interviews with raters blinded to subject ascertainment status. We used an empirically derived profile 
from the CBCL consisting of an aggregate t-score from the Attention, Anxiety/Depression and Aggression subscales (CBCL-
BP profile) to operationalize the presence or absence of BP symptoms. Receiver operating characteristic (ROC) curves were 
used to examine the ability of the CBCL-BP profile to identify children with and without a structured interview diagnosis of 
BP-I disorder. 
Results: The sample consisted of 661 subjects (mean age: 11.7 ± 3.3 years, 57% male and 94% Caucasian). In total, 20 percent 
of participants (n = 130) met structured interview criteria for a full diagnosis of BP-I disorder. The ROC analysis of the CBCL-
BP profile yielded an area under the curve (AUC) of 0.91. A t-score of ≥ 195 on the CBCL-BP profile correctly classified 86% 
of subjects with BP-I disorder with 80% sensitivity, 87% specificity, 61% positive predictive value (PPV) and 95% negative 
predictive value (NPV). 
Conclusion: The CBCL-BP profile efficiently discriminated pediatric subjects with and without a structured interview 
diagnosis of BP-I disorder. Findings suggest that the CBCL-BP profile may be an efficient tool to help identify children who 
are very likely to suffer from BP-I disorder. 
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Introduction 
Pediatric bipolar (BP) disorder is a prevalent and 
highly morbid disorder estimated to afflict up to 2% 
of youth worldwide (1, 2). Youth afflicted with BP 
disorder are at high risk for a wide range of adverse 
outcomes including psychiatric hospitalizations, 
substance use disorders and suicidality (3–7). 
However, because the diagnosis of pediatric BP 
disorder requires a level of clinical expertise that is 
not readily available, improved efforts to help 
identify children who may have BP disorder could 
greatly facilitate the identification of a sizeable group 
of children at high risk for adverse outcomes.  
While structured diagnostic interviews have been 
developed for research studies to aid in the diagnosis 
of pediatric BP disorder, these tools are not practical 
to use in clinical practice since they are lengthy, costly 
and not widely available. Consequently, simpler 
diagnostic aids are needed to help identify children 
who may have pediatric BP disorder.  
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One possible diagnostic aid is the Child Behavior 
Checklist (CBCL) (8). The CBCL is an empirically 
derived broadband assessment tool of psycho-
pathology with excellent psychometric properties 
that has been translated into over 100 languages and 
is an easy to use paper and pencil instrument. A body 
of research (9–12) and a meta-analysis (13) have 
shown very high correspondence between a unique 
profile of the CBCL consisting of elevations in the 
Attention, Anxiety/Depression and Aggression 
subscales greater than two standard deviations (SDs) 
above the norm (≥ 210 combined) with structured 
diagnostic interview derived clinical diagnosis of 
pediatric BP disorder (hence termed the CBCL-BP 
profile). However, because some studies failed to 
find an association between the CBCL-BP profile 
and a diagnosis of pediatric BP disorder, (14–18), 
there is a clear need for further evaluation of the 
utility of the CBCL to help identify children who may 
have BP disorder. 
Further evidence as to whether the CBCL-BP 
profile can help identify children who may have 
pediatric BP disorder has important implications. 
Considering the high morbidity and disability 
associated with BP disorder and its unique 
therapeutic needs, evidence supporting the CBCL-
BP profile’s diagnostic utility to help identify children 
suspected of suffering from BP disorder could be 
very useful for mental health practitioners and 
primary care physicians worldwide. Whether a child 
is affected with BP disorder is particularly relevant in 
the differential diagnosis of a child presenting with 
mood instability. If a child suffers from BP disorder 
and is started on an antidepressant or stimulant 
medication instead of an anti-manic treatment, they 
are at risk for worsened symptoms including 
suicidality and psychiatric hospitalization (19–22).  
The main aim of this study was to re-examine the 
diagnostic efficiency of the CBCL-BP profile for 
identifying pediatric BP-I disorder in a large sample 
of children with and without BP-I disorder. To this 
end, we applied conditional probability analysis and 
a receiver operator curve (ROC) analysis to four large 
data sets of children with ADHD, BP-I disorder and 
controls of both sexes that included close to 700 
youth. We also sought to determine the best cutoff 
point for the CBCL-BP profile for predicting a 
structured diagnostic interview derived diagnosis of 
pediatric BP-I disorder. Based on the literature and 
our previous work, we hypothesized that the CBCL-
BP profile would be highly predictive of a clinical 
diagnosis of pediatric BP-I disorder. 
 
Patients and methods 
Sample 
The sample was derived from four independent 
studies using identical assessment methodology: 1) 
and 2) were prospective controlled family studies of 
boys and girls 6 to 17 years of age with and without 
DSM-III-R ADHD (Boys Study: n = 140 ADHD 
and n = 120 Controls; Girls Study: n = 140 ADHD 
and n = 122 Controls) (23, 24); 3) was a prospective 
controlled family study of youth 10 to 18 years of age 
with (n = 105) and without (n = 98) DSM-IV 
pediatric BP-I disorder (25); and 4) was a prospective 
family study of youth 6 to 17 years of age of both 
sexes with active symptoms of  DSM-IV BP-I 
disorder (n = 105) (4). The ADHD studies recruited 
subjects from pediatric and psychiatric clinics. The 
BP-I disorder studies recruited subjects from 
referrals to the Clinical and Research Programs in 
Pediatric Psychopharmacology at the Massachusetts 
General Hospital and through advertisements in the 
community. Controls were recruited from pediatric 
clinics, advertisements to hospital personnel and 
community newspapers and internet postings. All 
studies excluded adopted subjects, subjects where the 
nuclear family was not available, subjects with major 
sensorimotor handicaps, autism, inadequate 
command of the English language or full scale IQ < 
70 (< 80 for ADHD studies). Potential subjects were 
also excluded from the ADHD studies if they had a 
primary psychotic disorder and from the BP-I 
disorder studies if their BP-I disorder was due solely 
to a medication reaction. For all four studies, parents 
provided written informed consent to participate. 
Children and adolescents provided written assent to 
participate. The Partners Human Research 
Committee approved these studies. 
 
Assessment procedures 
In all four studies, psychiatric assessments of subjects 
were made with the Kiddie Schedule for Affective 
Disorders – Epidemiologic Version (KSADS-E) 
(26–28). The K-SADS-E is a semi-structured 
interview tool used in research that assesses for the 
presence or absence of past and current symptoms 
within diagnostic categories. Extensively trained and 
supervised psychometricians with undergraduate 
degrees in psychology conducted all interviews. For 
the ADHD studies and the controlled BP disorder 
study, raters were blind to the ascertainment status of 
the families. For the BP disorder family study, raters 
were blind to the study assignment and whether the 
subject was a proband or sibling. 
Diagnoses were based on independent interviews 
with parents and direct interviews with children older 
than 12 years of age. Data were combined such that 
endorsement of a diagnosis by either reporter 
resulted in a positive diagnosis. For the sample used 
in this study, 46.9% (n = 310) of the assessments 
were based on the parent interview only. For the 
assessments where parents and children were both 
interviewed there was agreement between reporters 
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in 30.4% of subjects (n = 201), disagreement between 
reporters in 4.8% of subjects (n = 32), and no 
information available on the presence or absence of 
agreement between reporters for 17.9% of subjects 
(n = 118). In the subjects where there was 
disagreement between parents and children, 28 
diagnoses of BP disorder were made based on parent 
report, and four diagnoses of BP disorder were made 
based on child report. 
To assess the reliability of our overall diagnostic 
procedures, we computed kappa coefficients of 
agreement by having experienced, blinded, board-
certified child and adult psychiatrists and licensed 
experienced clinical psychologists diagnose subjects 
from audiotaped interviews made by the assessment 
staff. Based on 500 assessments from interviews of 
children and adults, the median kappa coefficient was 
0.98 for the ADHD studies and the controlled BP 
disorder study and 0.99 for the BP disorder Family 
study.  
Socioeconomic status (SES) was measured using 
the 5-point Hollingshead scale. A higher score 
indicates being of lower socioeconomic status (29). 
 
CBCL 
The parent of each participant completed the 1991 
version of the CBCL for ages 4 to 18 years. The 
CBCL queries the parent about the child’s behavior 
in the past six months and aggregates this data into 
behavioral problem t-scores (8, 30). A computer 
program calculates the t-scores for each scale. Raw 
scores are converted to gender and age standardized 
scores (t-scores having a mean of 50 and SD of 10). 
A minimum t-score of 50 is assigned to scores that 
fall at percentiles of ≤ 50 on the syndrome scales to 
permit comparison of standardized scores across 
scales. t-scores above 70 (2 SD) indicate clinical 
disorder. Subscales include Anxious/Depressed, 
Withdrawn/Depressed, Somatic Complaints, Social 
Problems, Thought Problems, Attention Problems, 
Rule-Breaking Behavior and Aggressive Behavior. 
 
Statistical analysis 
We first compared demographic characteristics 
between subjects with and without BP-I disorder in 
each of the studies separately and then in the 
combined sample using Student’s t-test for 
continuous outcomes, Pearson’s χ2 test or Fisher’s 
exact test (for expected counts < 5) for binary 
outcomes and Wilcoxon rank-sum test for ordinal 
outcomes. Next, we calculated conditional 
probabilities for each of the studies separately using 
a conservative cut-off point of ≥ 180 for the CBCL-
BP profile. We subsequently combined the data from 
the four studies and used receiver operating 
characteristic (ROC) curves to examine the ability of 
the CBCL-BP profile to identify those with and 
without a structured interview diagnosis of BP-I 
disorder. ROC analysis uses each value across the 
entire range of scores for the CBCL-BP profile as the 
cutoff for defining a case and compares this 
classification to the “true” diagnosis, as defined by 
the clinical interview. The ROC analysis then plots 
the false positive rate (1-specificity) and the true 
positive rate (sensitivity) for each value of the CBCL-
BP profile on the x- and y-axis, respectively, to create 
the ROC curve. Starting in the lower right-hand 
corner of the plot, each successive point corresponds 
to an increase in one point of the CBCL-BP profile. 
ROC analysis summarizes diagnostic efficiency with 
the AUC statistic. An AUC of 0.5 means the test does 
not predict the disorder in any way and an AUC of 
1.0 means the test predicts the disorder perfectly. We 
used conditional probabilities to examine the 
diagnostic utility of various cutoff points. For each 
cutoff, we calculated sensitivity, specificity, PPV, 
NPV and the percent correctly classified.  
Furthermore, using the same methods as described 
above, we performed a sensitivity analysis in a 
restricted sample consisting of subjects for whom 
there was no disagreement regarding the presence or 
absence of BP-I disorder (n = 511) . The restricted 
sample included subjects where the K-SADS-E 
assessment was based on parent interview only and 
subjects where there was agreement between parent 
and child report.  
All analyses were performed using Stata® (Version 
14).  
 
Results 
Demographic characteristics of the sample 
Subjects from the four original independent samples 
were only included in this sample if a CBCL was 
completed. Table 1 shows the demographic details 
from the four contributing samples. In examining 
differences between children with and without BP-I 
disorder in the controlled family study of BP-I 
disorder, children with BP-I disorder were more 
likely to be Caucasian (p ≤ 0.001). There were no 
meaningful differences between children with and 
without BP-I disorder in the ADHD studies. In the 
combined group that included the four contributing 
samples, children with BP-I disorder were more 
likely to be male (p = 0.002). No other meaningful 
differences were found within the combined sample 
in age, socioeconomic status or race. 
 
Diagnostic utility of the CBCL for identifying BP-I Disorder 
 
 
32 
 
TABLE 1. Demographic characteristics of those with and without BP-I disorder from the individual studies and all studies combined 
 Boys ADHD study Girls ADHD study BP disorder controlled study BP disorder family study All studies combined   
 No BP disorder 
n = 238 
BP disorder 
n = 13 
No BP disorder 
n = 211 
BP disorder 
n = 9 
No BP disorder 
n = 82 
BP disorder 
n = 64 
No BP disorder 
n = n/a 
BP disorder 
n = 44 
No BP disorder 
n = 531 
BP disorder 
n = 130 Test statistic p-value 
 Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD   
Age 11.1 ± 3.3 10.3 ± 3.3 11.7 ± 3.2 11.0 ± 3.3 13.5 ± 2.1 13.7 ± 2.4 n/a 9.2 ± 3.4 11.7 ± 3.2 11.7 ± 3.6 t659 = 0.08 0.94 
Socioeconomic 
statusa 1.7 ± 0.9 2.1 ± 1.0 1.8 ± 0.9 1.8 ± 0.7 1.6 ± 1.0 1.9 ± 1.2 n/a 1.8 ± 1.0 1.7 ± 0.9 1.8 ± 1.1 z = -1.29 0.20 
 n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)   
Male 238 (100) 13 (100) 0 (0) 0 (0) 48 (59) 43 (67) n/a 34 (77) 286 (54) 90 (69) Χ2 = 10.06 0.002 
Caucasianb 238 (100) 13 (100) 192 (93) 9 (100) 58 (76) 62 (98)* n/a 38 (86) 488 (94) 122 (95) Χ2 = 0.10 0.76 
Note. ADHD = attention deficit hyperactivity disorder; BP = Bipolar 
aSocioeconomic status (SES) was measured using the 5-point Hollingshead scale. A higher score indicates being of lower SES. Not everyone has SES reported. 
Smaler sample sizes for this measure were: boys ADHD study: 251; girls ADHD study: 219: BP controlled study: 108; all studies combined: 622.  
bNot everyone has race reported. Smaller sample sizes for this measure were: girls ADHD study: 215, BP disorder controlled study: 139; all studies combined: 649. *Significant difference in percent Caucasian between those with and without bipolar 
disorder in the BP-I disorder controlled study, p < 0.001 
 
 
 
Conditional probability analysis 
 
TABLE 2. Sensitivity, specificity and percent correctly classified using the Child Behavior Checklist-Bipolar (BP) profile with ≥ 180 to identify 
youth with BP-I disorder in each study 
Study Sensitivity (%) Specificity (%) Correctly classified (%) 
Boys ADHD study (n = 251) 85 74 74 
Girls ADHD study (n = 220) 89 74 75 
BP disorder controlled study (n = 146) 89 93 91 
BP disorder family study (n = 44) 91 n/aa 91 
Note. ADHD = attention deficit hyperactivity disorder 
aSpecificity could only be calculated for studies that included control subjects 
 
 
As shown in Table 2, similar values of sensitivity, specificity and percent correctly classified with BP-I disorder were observed in each individual study using the 
conservative cut-off point of ≥ 180 for the CBCL-BP profile (Table 2). 
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ROC analysis 
 
 
 
 
 
 
 
 
 
 
TABLE 3. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and percent correctly classified in 
the use of the Child Behavior Checklist-Bipolar (BP) profile t-scores to identify youth with BP-I disorder in the total sample from all 
four studies (n = 661) 
CBCL-BP profile 
Cut-point 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
Correctly classified 
(%) 
≥ 165 95 63 39 98 69 
≥ 180 89 77 49 97 79 
≥ 195* 80 87 61 95 86 
≥ 210 61 94 72 91 88 
≥ 225 39 97 79 87 86 
≥ 240 15 99 86 83 83 
* A cut-point of 195 for the CBCL-BP profile had the best properties to correctly identify subjects with a diagnosis of BP-I disorder as 
determined by the AUC 
 
 
 
 
Since all the studies used nearly identical 
methodology and assessments and had similar 
conditional probability analysis results, we combined 
data from the four samples for this analysis to 
improve statistical power. Thus, our combined 
sample consisted of 661 subjects, of which 130 
(19.7%) had BP-I disorder. Figure 1 depicts the 
combined t-scores from the four studies for the 
CBCL-BP profile that yielded an AUC of 0.91. 
Examination of the performance of specific cut off 
t-scores that correspond to 0.5 SD increases on the 
CBCL-BP profile to correctly identify subjects with a 
diagnosis of BP-I disorder showed that a cut-point 
of 195 had the best properties as determined by the 
AUC with 80% sensitivity, 87% specificity, 61% 
PPV, 95% NPV, and 86% correctly classified with 
BP-I disorder (Table 3). 
 
Sensitivity analysis using a restricted sample 
We found similar findings in our sensitivity analysis 
using the restricted sample as we did in the full 
sample. In the combined sample there were 87 
subjects (17%) who had BP-I disorder. There was no 
significant difference (p = 0.06) in mean age between 
FIGURE 1. Receiver operating characteristic (ROC) curve of the Child Behavior Checklist-Bipolar 
Profile T-scores in subjects from the total sample with and without Bipolar I disorder (n = 661) 
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subjects with BP-I disorder (10.3 ± 3.5 years) and 
those without BP-I disorder (11.0 ± 3.2 years). The 
ROC analysis of the CBCL-BP profile yielded an 
AUC of 0.93. A t-score of ≥ 195 on the CBCL-BP 
profile was the best cut-off score and correctly 
classified 87% of subjects with BP-I disorder with 
86% sensitivity, 87% specificity, 58% PPV and 97% 
NPV. 
 
Discussion 
ROC analysis using data from four independent large 
data sets of children with and without a structured 
interview derived diagnosis of BP-I disorder showed 
that a combined t-score of 195 on the CBCL-BP 
profile efficiently identified children with pediatric 
BP-I disorder. These results support and extend 
previous results (9–13) and provide strong evidence 
that the CBCL-BP profile is a useful tool to help 
identify youth who may have BP-I disorder. 
Although our results demonstrating the very high 
efficiency of the CBCL-BP profile in identifying 
children with pediatric BP-I disorder are consistent 
with previous research in a sample of youth with and 
without ADHD and their siblings (10), in a sample 
of Brazilian children (12), and in a meta-analysis (13), 
data from two community samples of treatment-
seeking youth did not find an association between the 
CBCL-BP profile with pediatric BP spectrum 
disorder (18, 31). Although the reasons for these 
discrepancies are not entirely clear, several 
explanations are plausible. Subjects in these 
community samples were assessed by community 
clinicians with varied clinical skills and diagnostic 
traditions without the benefit of a structured 
diagnostic interview (18, 31) raising the possibility 
that differences in assessment methodology may 
have accounted for the negative findings. It is also 
possible that CBCL-BP profile may be less accurate 
in children with pediatric BP spectrum disorders 
relative to children with more narrowly defined BP-I 
disorder. For example, Diler et al. reported more 
modest ROC results in a sample with a broader BP 
disorder phenotype in which the AUC for the CBCL-
BP profile was moderately accurate (0.72–0.78) (16). 
It is also noteworthy that while Volk et al. failed to 
find an association between a ≥ 210 cut-off on the 
CBCL-BP profile and a diagnosis of pediatric BP 
disorder in a large population sample of twins (14), 
this profile was associated with significant morbidity 
including social and school problems as well as 
increased suicidal behaviors. As suggested by the 
findings of our analysis showing that the optimal cut-
off score was ≥ 195, it is possible that the absence of 
an association between the CBCL-BP profile and 
pediatric BP disorder in the Volk et al. study may be 
related to their use of a higher cut-off score of 210 
for the profile. More work is needed to further 
evaluate these issues. 
While the AUC for the CBCL-BP profile was very 
high in our analysis, the modest PPV suggests some 
children with an elevated CBCL-BP profile will not 
meet criteria for BP-I disorder when evaluated 
clinically. On the other hand, the high NPV value 
indicates that a clinician can be confident that a child 
does not have BP-I disorder if the CBCL-BP profile 
is not elevated. Nevertheless, it is important to stress 
that the CBCL-BP profile should not be used as a 
diagnostic tool but rather as a diagnostic aid. 
Our findings documenting the very high efficiency 
of the CBCL-BP profile to identify children with a 
structured interview derived diagnosis of BP-I 
disorder has important clinical implications. With the 
limited behavioral health resources available 
worldwide, the CBCL-BP profile can greatly facilitate 
the identification of children at very high risk for BP 
disorder in community mental health clinics and 
within the primary care setting. The early 
identification of children at-risk for BP disorder can 
lead to the implementation of early intervention 
strategies that could mitigate the poor outcomes 
associated with pediatric BP disorder. Furthermore, 
the wide availability of the CBCL allows for cross-
cultural identification of children with the CBCL-BP 
profile, which could be used to improve our 
understanding of this phenotype across the world. 
Our findings need to be viewed with consideration 
of some methodological limitations. Although the 
raters who administered the structured interview 
were highly trained and supervised, they were not 
clinicians. Despite this, there were strong kappa 
coefficients of agreement between the lay 
interviewers and expert clinicians. Moreover, in one 
of the source studies (the family study of BP 
disorder), the diagnosis of BP-I disorder relied on a 
clinical assessment by an experienced clinician with 
expertise in pediatric BP-I disorder (JW). Finally, 
since part of the sample was referred and mostly 
Caucasian, our findings may not generalize to 
community samples and other ethnic groups. 
Despite these limitations, our work suggests the 
CBCL-BP profile is an efficient, simple to use tool 
that can help identify children who may have 
pediatric BP-I disorder who may benefit from further 
clinical assessment.  
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